Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease

Thyroid

Volumn 20, Issue 9, 2010, Pages 949-954

  Choo, Young Kwang ^a   Yoo, Won Sang ^a   Kim, Dong Woo ^a   Chung, Hyun Kyung ^a  

^a Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTRIX; THIAMAZOLE; THYROID PEROXIDASE ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXOPHTHALMOS; FEMALE; GOITER; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; THYROID WEIGHT; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

ADULT; ANTITHYROID AGENTS; AUTOANTIBODIES; EXOPHTHALMOS; FEMALE; GOITER; GRAVES DISEASE; HUMANS; HYPOTHYROIDISM; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; METHIMAZOLE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; THYROTROPIN; THYROXINE;

EID: 77956506008     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0126     Document Type: Article

References (22)

1. Franklyn J 1994 The management of hyperthyroidism. N Engl J Med 330:1731-1738.
2. Cooper D 2005 Antithyroid drugs. N Engl J Med 352: 905-917.
3. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD 1989 Antithyroid drugs in the treatment of hyperthyroidism of Graves disease: long-term follow-up of 434 patients. Clin Endocrinol (Oxf) 31:209-218.
4. Schleusener H, Schwander J, Fisher C, Holle R, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR, Schrnthander G, Schatz H, Packardt CR, Kotulla P 1989 Prospective multicenter study on the prediction of relapse after antithyroiddrug treatment in patients with Graves disease. Acta Endocrinol 120:688-701.
5. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical feature of patients with Graves disease undergoing remission after antithyroid drug treatment. Thyroid 3:369-375.
6. Benker G, Rienwein D, Kahaly G, Tegler L, Alexander WD, Faßbinder J, Hirche H; the European multicenter trial group of the treatment of hyperthyroidism with antithyroid drugs 1998 Is there a methimazole dose effect on remission rate in Graves disease? Results from a long-term prospective study. Clin Endocrinol (Oxf) 49:451-457.
7. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P 1998 The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves disease with antithyroid drugs. Thyroid 9:119-124.
8. Ross DS, Daniels GH, Gouveia D 1990 The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patients endocrine clinic. J Clin Endocrinol Metab 85:4347-4353.
9. Brokken LJ, Scheenhart JW, Wiersinga WM, Prummel MF 2001 Suppression of serum TSH by Graves Ig: evidence for a functional pituitary TSH receptor. J Clin Endocrinol Metab 86:4814-4817.
10. Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ 1996A comparison of 20 or 40mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) 45:511-516.
11. Volpe R 2004 Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4:217-223.
12. McGregor AM, Peterson MM, McLachlan SM, Rooke P, Smith BR, Hall R 1980 Carbimazole and the autoimmune response in Graves disease. N Engl J Med 303:302-307.
13. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I 1987 Induction of circulating activated suppressor-like Tcells by methimazole therapy for Graves disease. N Engl J Med 316:15-22.
14. Tsatsoulos A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM 1995 Increased serum interleukin-1 beta during treatment of hypothyroidism with antithyroid drugs. Eur J Invest 25:654-658.
15. Corrales JJ, Lopez A, Ciudad J, Mories MT, Miralles JM, Orfao A 1997 Methimazole therapy in Graves disease influences the abnormal expression of CD69(early activation antigen) on T cells. J Endocrinol 155:491-500.
16. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T 1991 Administration of thyroxine in treated Graves disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324:947-953.
17. Grebe SK, Feek CM, Ford HC, Fagerstrom JN, Cordwell DP, Delahunt JW, Toomath RJ 1998A randomized trial of shortterm treatment of Graves disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol 48:585-592.
18. Paschke R, Vogg M, Kristoferitsch R, Aktuna D, Wawschinek O, Eber O, Usadel KH 1995 Methimazole has no dose-related effect on the intensity of the intrathyroidial autoimmune process in relapsing Graves disease. J Clin Endocrinol Metab 80:2470-2474.
19. Prummel MF, Brokken LJ, Meduri G, Misrahi M, Bakker O, Wiersinga WM 2000 Expression of the thyroid stimulating hormone-receptor in the follicular stellate cells of the human anterior pituitary gland. J Clin Endocrinol Metab 85: 4347-4353.
20. Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee S, Kim KW, Chung JH 2006 Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves patients. Thyroid 12:1251-1257.
21. Tamai H, Kasagi K, Takaichi T, Takamatsu J, Komaki G, Matsubayashi S, Konishi J, Kuma K, Kumagai LF, Nagataki S 1989 Development of spontaneous hypothyroidism in patients with Graves disease treated with antithyroid drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 69:49-53.
22. Hamada N, Ito K, Mimura T, Ishikawa N, Momotani N, Noh J, Hosoda Y, Morii H 1987 Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves disease. Acta Endocrinol (Copenh) 114:328-335.